BioAffinity Technologies

Home
United States
San Antonio, TX
BioAffinity Technologies

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and targeted cancer treatment.

The Company’s first product, CyPath® Lung, is a noninvasive test for people at high risk for lung cancer.

12/22/2025

When Barry Manilow publicly shared his lung cancer diagnosis, his story underscored a powerful truth: early detection saves lives.
Too often, lung cancer is found late. At bioAffinity Technologies, we’re working to change that with CyPath® Lung, our noninvasive, sputum-based test designed to help identify cancer as early as Stage 1A.
We wish Mr. Manilow the best for a full and speedy recovery.

12/03/2025

Proud to announce our Chief Medical Officer, Gordon Downie, MD, PhD, will present recent case studies at the American Cancer Society National Lung Cancer Roundtable on Monday, December 8, 2025, from 2:35-3:15 p.m. ET.
His poster highlights three challenging patient cases in which CyPath® Lung helped identify Stage 1A lung cancer despite conflicting or inconclusive diagnostic data.

Read the full press release and view the poster here➡ https://bit.ly/3MdSP8i

11/26/2025

Would CyPath® Lung be right for your patient?

11/25/2025

Congratulations, Dr. Rodriguez!

11/19/2025

Since April 2024, Dr. Sai Karan Vamsi Guda has incorporated CyPath® Lung into his practice:
“For patients with small pulmonary nodules, six millimeters or larger, we utilize CyPath® Lung to be able to risk stratify them.”

Want to learn how CyPath® Lung can support your practice? Reach out to admin@bioaffinitytech.com

11/14/2025

We continued to see rapid growth and meaningful progress in Q3 2025:
⚫️CyPath® Lung volumes up 97% YTD
⚫️ Record Q3 sales, up 92% from Q2
⚫️ Testing revenue up 122% YoY
⚫️ New U.S. patent issued for our diagnostic algorithm
⚫️Raised $10.4M to support operations and growth
⚫️Returned to full Nasdaq Capital Market compliance
⚫️Added Roberto Rios, CPA, and John J. Oppenheimer, M.D., to our Board
“Our focus on expanding CyPath® Lung adoption, especially within the VA, is delivering results,” said CEO Maria Zannes.
Read the full announcement on our website ➡ https://bit.ly/3JDLBcS

11/11/2025

Honoring Our Veterans

Today, we honor the courage and sacrifice of those who have served our nation. At bioAffinity Technologies, we observe Veterans Day by reaffirming our commitment to helping Veterans live longer and healthier lives through early detection of lung cancer. CyPath® Lung is now available to Veterans through the VA health system.

11/08/2025

Lung cancer is still the leading cause of cancer deaths globally. Yet fewer than 1 in 5 people eligible for low-dose CT (LDCT) screening actually get screened.
US guidelines recommend LDCT screening for smokers and former smokers at risk for developing lung cancer. Annual screening can reduce the lung cancer death rate by up to 20% by detecting tumors at early stages.
At bioAffinity Technologies, we’re advancing noninvasive diagnostics like CyPath® Lung, designed to help physicians detect lung cancer early, when treatment is most effective and lives can be saved.
On Day, we join clinicians and advocates nationwide to raise awareness about lung cancer screening and improve accessibility to lifesaving LDCT screening.

11/07/2025

Best of luck to our VP of Sales, Dallas Coleman, as he represents CyPath® Lung in Charlotte, NC, at the Society for Advanced Bronchoscopy’s 2025 Pitch Party!
We’re honored to have Dallas share how CyPath® Lung is helping advance early detection and diagnosis in lung health.

11/06/2025

November is
Lung cancer is the leading cause of cancer death worldwide, yet early detection can make all the difference.
Lung cancer doesn’t just affect smokers. Anyone with lungs can be at risk. Many people don’t realize that up to 20% of those diagnosed have never smoked. Understanding the risks, and the importance of screening is key to saving lives.
At bioAffinity Technologies, we’re committed to advancing awareness and improving early detection through innovative science, including our noninvasive test, CyPath® Lung.
This month, we stand with patients, families, and healthcare providers working toward a future where lung cancer is found early and treated effectively.

11/05/2025

This , we’re happy to see continued strong momentum in the marketplace for CyPath® Lung, our noninvasive diagnostic aiding in early lung cancer detection.
October test volume rose 111% above the 2025 monthly average, reflecting steady physician adoption and growing clinical trust.
Learn more: https://bit.ly/4qL5v6h

10/21/2025

Day 2 at ! We're continuing great conversations with clinicians and researchers about advancing noninvasive lung diagnostics.
Stop by Booth 2242 to learn how CyPath® Lung uses flow cytometry and to support earlier, more accurate detection of lung cancer.

Address

3300 Nacogdoches Road Ste 216
San Antonio, TX
78217

Telephone

+12106985334

Website

https://bioaffinitytech.com/

Alerts

Be the first to know and let us send you an email when BioAffinity Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Featured

Psych Dimensions

Want your practice to be the top-listed Clinic in San Antonio?